Medicenna Therapeutics Return on Equity

Medicenna Therapeutics (MDNA) currently reports a ROE of -60.05%. That is below the Healthcare sector average of 29.39%. Use the charts on this page to explore Medicenna Therapeutics's ROE history and peer comparisons.

Medicenna Therapeutics's ROE of -60.05% is lower than the Healthcare sector average of 29.39%. That is roughly 304.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Medicenna Therapeutics's current -60.05% should be judged against Healthcare norms (sector average: 29.39%) and against MDNA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -60.05%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.39%. From there, open related valuation or income-statement pages for Medicenna Therapeutics, and consider following MDNA for alerts when major investors trade the stock.

Medicenna Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -60.05% versus a sector average near 29.39%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MDNA with unrelated industries.